Clinical Trial Update: Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study evaluating coadministration of 20vPnC with a booster dose of BNT162b2; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20vPnC (20-valent pneumococcal conjugate vaccine)
• BNT162b2 (tozinameran)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease, COVID-19 | Phase 3 | Status: COMPLETED | Results posted: 2022-12-14